Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release

BACKGROUND: Therapeutic options currently available for metastatic castration-resistant prostate cancer (mCRPC) do not extend median overall survival >6 months. Therefore, the development of novel and effective therapies for mCRPC represents an urgent medical need. T cell engagers (TCEs) have eme...

Descripción completa

Detalles Bibliográficos
Autores principales: Dang, Kevin, Castello, Giulia, Clarke, Starlynn C, Li, Yuping, Balasubramani, Aarti, Boudreau, Andrew, Davison, Laura, Harris, Katherine E, Pham, Duy, Sankaran, Preethi, Ugamraj, Harshad S, Deng, Rong, Kwek, Serena, Starzinski, Alec, Iyer, Suhasini, van Schooten, Wim, Schellenberger, Ute, Sun, Wenchao, Trinklein, Nathan D, Buelow, Roland, Buelow, Ben, Fong, Lawrence, Dalvi, Pranjali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183203/
https://www.ncbi.nlm.nih.gov/pubmed/34088740
http://dx.doi.org/10.1136/jitc-2021-002488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183203/
https://www.ncbi.nlm.nih.gov/pubmed/34088740
http://dx.doi.org/10.1136/jitc-2021-002488

Ejemplares similares